Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease

W. J. Sandborn; E. V. Loftus

doi:10.1136/gut.2003.020552

Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease

W. J. Sandborn, E. V. Loftus

Gastroenterology and Hepatology

Research output: Contribution to journal › Comment/debate › peer-review

62 Scopus citations

Original language	English (US)
Pages (from-to)	780-782
Number of pages	3
Journal	Gut
Volume	53
Issue number	6
DOIs	https://doi.org/10.1136/gut.2003.020552
State	Published - Jun 2004

ASJC Scopus subject areas

Gastroenterology

Access to Document

10.1136/gut.2003.020552

Cite this

@article{409106112d844a4ca25d92b03052ab88,

title = "Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease",

author = "Sandborn, {W. J.} and Loftus, {E. V.}",

year = "2004",

month = jun,

doi = "10.1136/gut.2003.020552",

language = "English (US)",

volume = "53",

pages = "780--782",

journal = "Gut",

issn = "0017-5749",

publisher = "BMJ Publishing Group",

number = "6",

}

TY - JOUR

T1 - Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease

AU - Sandborn, W. J.

AU - Loftus, E. V.

PY - 2004/6

Y1 - 2004/6

UR - http://www.scopus.com/inward/record.url?scp=2442668848&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2442668848&partnerID=8YFLogxK

U2 - 10.1136/gut.2003.020552

DO - 10.1136/gut.2003.020552

M3 - Comment/debate

C2 - 15138201

AN - SCOPUS:2442668848

SN - 0017-5749

VL - 53

SP - 780

EP - 782

JO - Gut

JF - Gut

IS - 6

ER -

Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this